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ABSTRACT 
PEO (Polyethylene Oxide) is one of the most important biodegradable polymers used in pharmaceutical 
formulations, mainly because of its non-toxicity, high water-solubility and swellability, insensitivity to the 
pH of the biological medium and flexibility during dosage form production (Kim, 1995; Picker-Freyer, 
2006; Kiss et al., 2008).  
 
The lack of studies attempting to achieve controlled drug delivery of hydrophilic drugs has provided us 
with motivation to use a drug of this nature but we have combined it with a PEO-electrolyte combination 
in order to control drug delivery. This study was aimed at modifying the physicochemical and 
physicomechanical properties of PEO in order to influence the hydrodynamic diffusion of its three-
dimensional network. Hence, through such alteration, it was envisaged that if drug is loaded into its 
PEO matrix, its solubility and dissolution can be regulated in order to achieve zero-order influx of 
dissolution medium. The interaction between PEO and electrolytes may allow for precipitation of ions on 
the polymer backbone. This would lead to the attraction of water molecules to the ions. As a result, this 
would cause dehydration of the polymer matrix, hence minimising its mobility and relaxation. 
 
In this study, 36 PEO-electrolyte combinations were prepared by combining a high molecular weight 
PEO with different statistically planned combinations of electrolytes. The 36 formulations were 
microscopically analyzed and subjected to textural analysis. The salted-out PEO-electrolyte 
combinations were then further selected and analyzed. Assessment of the molecular structural 
transition and thermal compatibility analysis indicated minimal interaction between the electrolytes and 
PEO indicating that the polymer-electrolyte combination was stable enough to be employed as a 
medium for controlled drug release. The polymer-electrolyte combination was combined with a model 
drug, diphenhydramine HCl to form a tablet matrix and then subjected to dissolution. In vitro drug 
release varied depending on the different electrolytes and their combinations. The type of polymer, 
molecular weight of the polymer, concentration of the polymer, different electrolyte combinations and 
solubility of the drug played a significant role in controlling drug release.  
 
After optimization of the fracture force, resilience and work performed values, results have established 
that equal concentrations of Na2CO3 and K2HPO4 are desirable for achieving controlled release of drug 
from the salted-out PEO combination in a zero-order manner. Furthermore, Na2CO3 and K2HPO4 had a 
significant influence on controlling the release of drug from the salted-out PEO combination due to 
crosslinking between PEO and the electrolytes ultimately leading to zero-order release kinetics. The 
salting-out of PEO notably modified the physicochemical and micromechanical properties of basic PEO, 
which demonstrably enhanced the ability of the sample to achieve controlled drug release. The 
formulation strategy employed in this study where in our sample drug, diphenhydramine HCl was 
combined with a PEO-electrolyte combination has shown promising results in regulating drug release. 
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SECTION 1 
LITERATURE REVIEW AND MOTIVATION FOR STUDY 
 
1.1  Introduction 
 
Polymers have found applications in diverse biomedical fields such as tissue 
engineering, implantation of medical devices, artificial organs, prostheses, 
ophthalmology, dentistry and bone repair (Jagur-Grodzinski, 1999; Dasgupta et al., 
2002; Aray et al., 2003; Dasbach et al., 2003; Alarcon et al., 2005). Polymer based 
delivery systems enable controlled slow release of drugs into the body. They also 
make possible the targeting of drugs to sites of inflammation or tumours (Jagur-
Grodzinski, 1999).  
 
Biodegradable polymers have become increasingly popular as carriers in the design 
of drug delivery systems (Park et al., 2005). Polymeric materials suitable for 
biomedical applications must be ‘biocompatible’ and ‘biodegradable’ and harmful 
degradation products should not be generated as a result of their biodegradation. 
Functional groups located on the polymer as well as its molecular structure are 
usually responsible for the biocompatibility and/or biodegradability of polymers and 
may impart either therapeutic or/and toxic characteristics. For examples, carboxylic 
groups induce therapeutic activity of many drugs (Jagur-Grodzinski, 1999). As these 
polymers degrade in the body to smaller molecular weight compounds that are either 
metabolized or excreted, they obviate the need for removal of the polymeric carrier 
after the drug load is bioeroded (Diamente et al., 2006; Duncan et al., 2006). In this 
    2 
regard, biocompatibility and lack of immunogenicity makes polyethylene oxide (PEO) 
an important polymer for biomedical and drug delivery applications (Harris, 1992; 
Harris and Zalipsky, 2000; Thompson et al., 2008). PEO is a free flowing, 
thermoplastic polymer synthesized by the heterogeneous catalytic polymerization of 
ethylene oxide monomer and is commercially available in a wide range of molecular 
weights (100,000–8,000,000g/mol) (Crowley et al., 2002). 
 
PEO is usually selected as the hydrophilic block with a role to provide a hydrated 
steric barrier in order to minimize the adsorption of circulating blood components 
(Park et al., 2005). When bound to an immunogenic substrate having a desirable 
function in the body, PEO tends to reduce or eliminate immune responses so that the 
organism can tolerate the substance (Dhawan et al., 2005). In addition, the PEO has 
been shown to prevent opsonization and facilitate the recognition of drug delivery 
carriers by the reticuloendothelial system (RES). Thus, these properties of PEO 
allow drugs to be administered over prolonged periods of time (Dunn et al., 1988; 
Park et al., 2002; Soo et al., 2002; Li et al., 2004; Park et al., 2005).  
 
PEO is an inherently dissipative polymer and a non-ionic surfactant of great scientific 
and technological interest for a wide variety of applications, many of which depend 
on the properties of the polymer in aqueous solution (Rosner, 2001). Inherently 
dissipative polymers are co-polymers with a high degree of resistivity (Rosner, 2001; 
Aray et al., 2003). PEO is one of the most important polymers used in 
pharmaceutical formulations, mainly because of its non-toxicity, high water-solubility 
and swellability, insensitivity to the pH of the biological medium and flexibility during 
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dosage form production (Kim, 1995; Picker-Freyer, 2006; Kiss et al., 2008). PEO is 
completely soluble in cold and warm water in all ratios due to hydration of the ether 
oxygen moiety on the polymer backbone (Hong et al., 2008). The inclusion of the 
oxygen atom within the polyethylene structure enhances its polar character, and 
facilitates the attraction of water and other ions (Rosner, 2001).  
 
PEO can be chemically modified and reacted with, or adsorbed onto, other 
molecules and surfaces. Sophisticated applications for PEO have increased the 
demand for PEO oligomers with tailored functionalities and hetero-bifunctional PEO 
is often needed. When bound to a water insoluble compound, the resulting PEO 
conjugate generally displays increased water solubility or dispersibility (Li et al., 1996; 
Harris et al., 2003; Zubarez et al., 2006). Since the repeating ether units of PEO are 
essentially non-reactive, these oligomers must be reacted with, or adsorbed onto, 
other compounds through terminal or pendant functional groups. Examples include 
PEO with thiol or carboxylic acid end groups that have been adsorbed onto metal or 
metal oxide surfaces (Otsuka et al., 2001; Zhang et al., 2002; Harris et al., 2003; 
Uchida et al., 2005; Zhang and Zhang, 2005; Zhang et al., 2007; Thompson et al., 
2008). 
 
1.2 The Role of Polyethylene Oxide in Controlled-Release Drug Delivery 
Systems 
Controlled release of therapeutic agents remains a huge challenge in drug delivery 
(Lyons et al., 2008). Repeated administration of a drug in order to maintain drug 
concentration within a therapeutic window may cause serious side effects, which in 
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many cases necessitates the patient to stop taking the medication (Geever et al., 
2006). With conventional dosage forms, high peak blood concentrations may be 
reached soon after administration with possible side-effects related to the transiently 
high concentrations (Lyons et al., 2008).  
 
The well-known properties of PEO and its regulatory acceptability have helped 
extend its application to various controlled-release drug delivery systems (Dhawan et 
al., 2005; Hong et al., 2008). PEO gels and other aggregates of PEO are also 
superior candidates for controlled drug delivery purposes (Aray et al., 2003).  
 
1.2.1 Release mechanisms from PEO-based monolithic drug delivery 
systems  
The release rate of a dissolved or dispersed drug from a polymeric matrix introduced 
in a specific environment strongly depends on the nature of the diffusion and sorption 
processes involving the polymer/environment system and the polymer/drug system. 
The various mechanisms that control drug release with respect to PEO are briefly 
discussed hereunder. 
 
i. Diffusion-controlled PEO matrices 
The dissolved drug will diffuse from a matrix which does not actively interact 
with the external environment according to an ordinary diffusion law.  
ii. Swelling-controlled PEO matrices 
Completely different drug release behavior is observed for hydrophilic 
polymers such as PEO when water sorption is followed by significant polymer 
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swelling. Zero-order release kinetics may be achieved which swells at a 
constant rate and with a constant penetration surface area, but only if the 
counter diffusion of the solute molecules is rapid compared to the swelling 
rate. 
iii. Intermediate cases 
There are intermediate cases in which both the swelling and the diffusive 
control of PEO are important during drug release.   
iv. Polymer swelling and dissolution-controlled PEO matrices 
Incorporation of hydrophilic polymers such as PEO into monolithic matrices 
leads to modification of drug release due to swelling and erosion of the 
polymers (Kim, 1998). PEO swells and forms a compact gel layer on the 
surface of the tablet which is responsible for the controlled drug release. Only 
once the gel layer is formed, can controlled release be expected. Prior to this 
point, formulations have almost immediate release dissolution profiles 
(Petrović et al., 2009). Either swelling or dissolution can be the predominant 
factor for a specific type of polymer, but in most cases drug release kinetics is 
a result of a combination of these two mechanisms (Lee and Lewis, 1981; 
Tahara et al., 1995; Effentakis and Buckton, 2002; Wu et al., 2005). The 
controlling mechanism of drug release from PEO tablets is dependent upon 
the drug solubility, drug loading, the addition of a water-soluble excipient, and 
the molecular weight of PEOs (Petrović et al., 2009). 
 
Among different technologies used in controlled drug delivery, hydrophilic matrix 
systems are the most popular because of the simplicity of formulation, ease of 
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manufacturing, low cost, FDA acceptance, and applicability to drugs with a wide 
range of solubility (Durig and Fassihi, 2002; Sako et al., 2002; Williams et al., 2002; 
Jamzad and Fassihi, 2006). Various factors can influence the drug release kinetics 
from hydrophilic matrices (Pillay and Fassihi, 1999; Jamzad et al., 2005). The main 
determining factors of a hydrophilic polymer-based matrix are the swellability and 
erodibility of the polymer matrix, as well as the diffusivity of drug molecules. Besides 
the concentration gradient between the dosage form and the release medium, this 
latter property depends highly on the size, molecular mass and solubility of the drug 
molecule, and the extent and nature of the drug–polymer interaction. On the other 
hand, swellability and the erodibility of the matrix also depend on the molecular mass 
and hydration tendency of the polymer, as well as the interaction between polymer 
molecules. In the case of amorphous or partly amorphous polymers, this latter 
property can strongly be influenced by a phenomenon known as physical ageing. As 
such polymers are not in equilibrium below their glass transition temperature, they 
usually undergo spontaneous, although slow transformations towards low-energy 
equilibrium (Kiss et al., 2008). A study conducted by Kiss and co-workers (2006), 
revealed that physical ageing of two types of PEO could be tracked by the 
combination of differential scanning calorimetry, positron annihilation lifetime 
spectroscopy and scanning electron microscopy. Structural changes, i.e. an increase 
in the degree of crystallinity and volume relaxation could be observed even after a 
short storage time (4 weeks), which highlighted the importance of the effects of 
physical ageing on the properties of dosage forms comprising PEO (Kiss et al., 2006; 
2008). The effect of physical ageing on the drug release behavior of several 
polymers and lipids was studied and can be found in the literature but not for PEO 
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(Lovrecich et al., 1996; Vincente et al., 2000; Nafee et al., 2003; Zelkó and Süvegh, 
2005, Kiss et al., 2008).  
 
1.2.2 In Vitro versus in vivo drug release from PEO matrices 
PEO matrices can release drugs in vitro stably over a long period. However, it has 
also been shown that a matrix tablet consisting of drug and PEO failed to release the 
drug sufficiently in vivo, even though it successfully achieved extended release in 
vitro (Sako et al., 1996). This was due to a difference in hydration conditions which 
affected the formation of a hydrogel. Abundant water is available for the formation of 
a PEO hydrogel in the in vitro dissolution test, but the water content in the 
gastrointestinal tract (GIT) varies by site, i.e., there is ample water in the upper GIT 
(stomach and small intestine), but little water is available in the lower GIT including 
the colon. The discontinuous in vivo drug release from PEO matrices was caused by 
insufficient PEO hydration due to its slower rate of swelling. It was found that only 22% 
of the polymer in various formulations became hydrated within 2 hours. It has been 
reported that PEO matrices absorb water gradually to reach maximum swelling at 
approximately 8 hours, which is much longer than the time that the preparations 
were retained in the upper GIT, where digestive juices are abundant (Davis et al., 
1986; Wilding et al., 1995; Maggi et al., 2000; Kojima et al., 2008).  
 
A study by Kojima and co-workers (2008), demonstrated that a combination of 
polyethylene glycol (PEG) and PEO was useful as an oral controlled absorption 
system (OCAS). The aim was to develop a PEO-based matrix system that enabled 
the sustained release of a large quantity of a highly water-soluble drug over 24 hours. 
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The release property of PEO/PEG matrix tablets containing different percentages 
(10–75% by mass) of different drugs was evaluated and compared. PEO/PEG matrix 
tablets have the key features of rapid water uptake and the resulting complete 
gelation of its polymeric excipients within a few hours. In addition, the feasibility of 
using a counter polymer, which has the opposite charge to the drug, was evaluated 
as a tool for the decrease in diffusion of a large quantity of highly water-soluble drug. 
Diltiazem (DTZ), which is a basic compound, was used as a model drug with high 
solubility, and crosslinked carboxyvinyl polymer (CVP) was used as a model counter 
polymer. This study described by Kojima and co-workers (2008), correlates with this 
investigation in that both are aimed at extending drug release of a highly water 
soluble compound, but in this study, two polymers were combined rather than ions 
which is the focus of this investigation. The results demonstrated that drugs with 
higher water solubilities were released faster from the PEO/PEG matrices. The drug-
release rate also increased as the amount of drug content increased. The utilization 
of a polymer bearing a charge opposite that of the drug effectively restricted the 
diffusion of DTZ. As a result, the drug was released mainly by matrix erosion, which 
led to an extended release of 24 hours or longer, even with a high drug content (e.g., 
50% by weight). These results suggest that incorporating counter polymer(s) into 
PEO/PEG matrices may be an effective way to achieve sustained release of large 
amounts of highly water-soluble drugs with less pH dependency (Sako, 1998; Kojima 
et al., 2008).  
 
1.3 The Influence of Formulation Variables on the Drug Release Behavior 
from PEO Matrices  
    9 
Drug release characteristics of PEO have been studied and discussed in the 
literature (Kim, 1995; Maggi et al., 2002; Wu et al., 2005; Borgquist et al., 2006).  
Numerous studies have been performed with high and low molecular weight PEO, 
the combination of PEO with hydrophilic/hydrophobic drugs and with binary blends of 
two polymers. These studies are outlined hereunder.  
 
1.3.1 Investigations utilizing varying molecular weight polyethylene oxide 
PEO of different molecular weights can be used to control the release of drug due to 
their matrix forming properties and partly amorphous structure. PEO undergoes 
structural changes caused by elevated temperature and relative humidity of the 
storage medium resulting in increased drug release (Kiss et al., 2008). This physical 
process can be highly influenced by the structure of different drug molecules, such 
as polymer-binding ability and hydration tendency. Modification of the release 
kinetics is possible via selecting the appropriate grade of PEO (Maggi et al., 2002). 
Drug release from PEO matrices may follow zero-order kinetics, and is mainly 
governed by polymer swelling, erosion and diffusion of drug molecules. It has been 
reported that both swelling and dissolution are faster in the case lower molecular 
weight PEO that results in higher drug release rates. Conversely, the extent of 
swelling is higher for higher molecular weight PEO and this is the dominant factor in 
controlling drug release (Kiss et al., 2008).  
 
A study by Apicella and co-workers (1993), reviewed the drug release from 
monolithic water-swellable and soluble polymer tablets. The drug release behavior of 
l-hydroxyethyl-theophylline (etofylline) from compression-moulded tablets of 
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hydrophilic pure semi-crystalline PEOs of Mw=600,000g/mol and 4,000,000g/mol and 
of two blends of the two molecular weights of PEO were described. The drug release 
from the high molecular weight PEO was principally related to the material swelling 
rather than polymer dissolution, leading to a progressive decrease of the drug’s 
diffusive conductance in the growing swollen layer, and hence to a non-constant 
release induced by the prevailing diffusive control. Conversely, drug release from the 
low molecular weight PEO was strictly related to the polymer dissolution mechanism. 
This led to the achievement of stationary conditions wherein the rate of swelling 
equalled the rate of dissolution, and hence ensured a constant release rate. 
Intermediate behaviors were detected in the case of the two blends. The results 
indicated that it was possible to obtain different release behaviors by changing the 
molecular weight of the soluble polymeric matrix-forming monolithic drug delivery 
devices (Apicella et al., 1993). 
 
The thermal stability of PEO in sustained release tablets prepared by hot-melt 
extrusion was investigated by Crowley and co-workers (2002). The chemical stability 
of PEO was found to be dependent on both the storage and processing temperature 
as well as the molecular weight of the polymer. Storage of the polymer above its 
melting point significantly increased polymer degradation, and the degradation 
process was accelerated as the molecular weight was reduced (Crowley et al., 
2002). The results of this study provided sufficient motivation for me to utilise a high 
molecular weight PEO and to undertake investigations at room temperature so as to 
avoid potential degradation of PEO. 
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A study by Kiss and co-workers (2008), on two basic drugs, theophylline and 
metronidazole embedded into PEO matrices was characterized by molecular 
modelling and their effect on the change of drug release stability was revealed. The 
findings suggested that both the hydration properties of the active ingredients as well 
as the molecular masses of PEO influenced the effect of physical ageing of PEO on 
the drug release properties of the matrix. It was found that the formation of the 
theophylline–water complex led to higher energy gains than in the case of 
metronidazole-water complexes. Thus, theophylline was released easier from the 
PEO matrix, because its interaction with water molecules during storage possibly led 
to the weakening of the theophylline–PEO interaction. This phenomenon was less 
remarkable in the case of metronidazole, where drug–water interaction was weaker. 
The two different molecular mass forms of PEO behaved differently from this aspect, 
as PEO N-12K matrices presented equally increased drug releases of both kinds of 
molecules. On the other hand, PEO 303 formed a much thicker matrix, leaving less 
opportunity for the water molecules to get imbibed and interact with the drug 
molecules (Kiss et al., 2008). From this study, it was gauged that PEO 303 may be a 
better polymer to utilise for controlled release due its matrix forming properties.  
 
In this study conducted by Hong and co-workers (2008), an attempt was made to 
modify the release profile of nifedipine (NP) from the hydrophilic matrix PEO, 
containing solid dispersed NP, by restricting the drug releasing surface area. The 
restriction was created by applying polymeric barrier layers to both sides of the tablet 
using a viscous hydrophilic polymer, carbopol (CP) (Hong et al., 2008). The DSC 
thermogram and X-ray diffraction results indicated that the formation of crystalline 
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domain of NP and PEO was not detected. Swelling and morphological changes of 
the CP layer on both sides of the tablet minimized the erosional release for rapidly 
swelling PEO 200K, and thus changed the NP release to a diffusion-controlled 
process. For PEO 900K, the initial release rate was slower than that of PEO 200K, 
possibly due to the slower swelling and erosional release from the side of the tablet. 
For the PEO 7000K tablet capped with CP, much slower release was observed. 
Decreased surface area in contact with the medium by CP capping and the slower 
diffusion of NP molecules through the PEO and CP hydrogel seemed to work 
together. The physical mixture of PEO and CP delayed the release of NP 
remarkably. The increase in pH, ionic strength and buffer concentration of the 
dissolution medium decreased the release rate (Hong et al., 2008). This study once 
again indicates that higher molecular weight PEOs results in slower release rates 
that lower molecular weight PEOs. Addition of a polymeric barrier proved to be useful 
for prolonging drug release. 
 
Mini-matrices with release-sustaining properties were developed by hot-melt 
extrusion using metoprolol tartrate as model drug and ethylcellulose as sustained-
release agent. PEG or PEO was added to the formulation to increase drug release. 
Changing the hydrophilic polymer concentration and Mw modified the in vitro drug 
release: increasing concentrations yielded faster drug release (irrespective of Mw), 
whereas the influence of molecular weight depended on concentration. The 
sustained-release effect of the experimental formulations was limited, and relative 
bioavailabilities of 66.2% and 148.2% were obtained for 5% and 20% PEO 
1,000,000g/mol mini-matrices, respectively (Verhoeven et al., 2009).  
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The constant release of prostaglandin E, from crosslinked crystalline-rubbery 
hydrogel matrices based on PEO which were undergoing solvent sorption and from 
crystallites melting in aqueous environments was reported. In the case of 
uncrosslinked PEO matrices, the solubility of PEO can alter the characteristics of the 
penetrated layer, leading to different behaviors in systems presenting different 
dissolution features. To control the release of the active agent, there should be a 
balance between diffusion of the active agent and solubilization of the PEO matrix. 
The diffusivity of the drug through the matrix, the swelling of PEO, and its 
solubilization rate can be biased by changing the molecular weight of PEO or 
blending PEO fractions with different molecular weights (Maggi et al., 2002).    
 
Numerous other studies have also been performed with polyethylene oxide of high 
and low molecular weights (Apicella et al., 1993; Kim, 1995; Maggi et al., 2002; Wu 
et al., 2005; Petrović et al., 2009). 
 
1.3.2 Polyethylene oxide and hydrophobic/hydrophilic drugs 
Hydrophilic drugs are mainly released by diffusion of dissolved drug molecules 
across the PEO gel layer, while hydrophobic drugs are more likely released through 
erosion of the PEO gel (Aldermann, 1984; Maggi et al., 2002). Hydrophilic drugs 
diffuse through the gel-layer rapidly after water has penetrated a PEO matrix; 
therefore it is difficult to extend the drug release from these preparations. Due to this, 
it is necessary to control the drug release; especially when there is a high dose of the 
hydrophilic drug included, leading to the larger size of the matrix tablet (Kojima et al., 
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2008). The contribution of these two phenomena to the overall drug release process 
is influenced not only by drug solubility, but also by the physical and mechanical 
properties of the PEO gel layer that forms around the tablet. We have attempted to 
modify the PEO-matrix by combining it with ions in an attempt to overcome this 
difficulty associated with controlled release of hydrophilic drugs. 
 
In a study conducted by Agrawal and co-workers (2006), zero-order sustained 
release behavior for periods of up to 20 days for two hydrophobic drugs, sulindac 
and tetracaine, from solutions of poly(lactide)-poly(ethylene oxide)-poly(lactide) 
(PLA–PEO–PLA) triblock copolymer were observed. The drug release from 
drug/phosphate buffer solution (PBS) with no polymer was very quick, and the entire 
amount of drug was released in 4–6 hours. In the case of both sulindac and 
tetracaine, the drug/polymer/PBS systems did not demonstrate a burst type release 
profile, and release was much slower than in the drug/PBS system with no polymer. 
Difference in release rates for drugs with different chemical structures could suggest 
that the strong interaction of the drugs with the polymer may be a major reason for 
slow release of drugs from the polymer solution (Agrawal et al., 2006).  
 
In another study conducted by Dasbach and co-workers (2003), a composite disk 
compressed drug delivery system that provided upcurving and constant drug delivery 
was developed. The objective of that study was to modify the release of a hydrophilic 
drug utilizing PEO in a compression-coated controlled release tablet. Three different 
core tablets, compression coated with 200mg, 300mg, and 400mg PolyoxTM (Dow 
Chemical Company, Michigan, USA) were used. The first tablet contained 100% 
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tramadol HCl. The second tablet contained 90% tramadol HCl and 10% EthocelTM 
(Dow Chemical Company, Michigan, USA) and the third tablet contained 90% 
diphenhydramine HCl and 10% EthocelTM (Dasbach et al, 2003). For both actives, 
the presence of the compression coating provided an initial lag and extended the 
drug release. As the PolyoxTM coating was doubled in mass on the core tablets 
containing EthocelTM, the release of the diphenhydramine HCl was found to decrease 
from 66% to 25% after 6 hours (Dasbach et al, 2003). The tablet matrices containing 
only tramadol HCl in the core were found to have the largest weight gain over a 24 
hour period compared to tablets that contained the drug and EthocelTM. The 
presence of EthocelTM in the core did not typically impact the swelling characteristics 
of the tablets (Dasbach et al., 2003). 
 
1.3.3 Binary blends of two polymers to modify drug release 
This example outlines the use of PEO and polycaprolactone (PCL) blends in the 
production of monolithic matrices for oral drug delivery as well as the role of 
interfacial adhesion between PCL/PEO and drug (Park et al., 2005; Lyons et al., 
2008). Several batches of matrix material were prepared with carvedilol. Dissolution 
testing indicated that the incorporation of the hydrophobic PCL polymer into a PEO 
matrix resulted in a retarded drug release profile with the degree of retardation being 
proportional to the amount of PCL in the matrix. The matrices prepared in this work 
demonstrate that the rate of drug release in a PEO/PCL monolithic matrix can easily 
be tailored by simply altering the composition of the binary blend. Matrices with 
higher loading of carvedilol were seen to release the active agent at a slightly quicker 
rate than those with lower loadings. This is thought to be due to less rate controlling 
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polymer (Lyons et al., 2008). The interfacial adhesion between water and PCL/PEO 
was increased with increasing the PEO content due to the greater hydrophilicity of 
PEO. The drug release rate of the microcapsules was significantly increased as the 
PEO content increased, which could be attributed to an increase in the hydrophilic 
groups or the degree of adhesion at the interfaces. This indicates that the release 
rate of drug can be controlled with varying the PEO content (Park et al., 2005). 
 
1.4 The Interaction of Polyethylene Oxide with Various Ions 
Table 1.1 provides a detailed illustration of the interaction of PEO with various ions. 
A typical example of the interaction between ions and PEO is in the area of bone 
repair. Bonding of foreign materials with bones may take place when a layer of 
apatite [Ca5(PO4)3(OH)], similar to bone in crystallinity and composition, is 
spontaneously deposited on their surface in contact with blood plasma. 
Biocompatible materials, which will provide a matrix for the in vivo formation of 
hydroxyapatite deposits, may be suitable for bone repair. After solvent extraction of 
its cytotoxic components and pre-treatment with -glycidyl-oxypropyl 
trimethoxypropane, it is reacted with the amino-end-capped PEO. When the treated 
material is immersed in a calcification solution, a continuous layer of calcium 
hydrogen phosphate (CaHPO4) is formed in vitro. This complexation of calcium ions 
by PEO chains may be expected to provide strong bonds between the inorganic 
crystals and the polymeric network (Jagur-Grodzinski, 1999). 
 
This literature review has outlined the various avenues where PEO has been utilized 
in controlling drug delivery. Numerous studies have been conducted using high and 
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low molecular weight PEOs to improve drug delivery. Hydrophilic and hydrophobic 
drugs have also been incorporated with PEO to improve their solubility and hence 
drug delivery. PEO matrix tablets that have achieved the sustained release of 
diclofenac Na (solubility: 25mg/ml in water) for over 12 hours were formulated (Kim, 
1998). However, in another study, PEO tablets containing 49% (by weight) of the 
highly water-soluble drug, i.e., diltiazem hydrochloride (solubility: >100mg/mL in 
water) extended drug release for only 8 hours (Maggi et al., 2002). To date, no 
publications have reported on the quantitative assessment from the contribution of 
drug diffusion and polymeric erosion to the release process of PEO-based matrices. 
In addition, there have been no reports of any PEO-based matrix tablets that have 
achieved the sustained release of a large amount of highly water-soluble drug for 24 
hours. So far, acetaminophen is the only drug to be incorporated into a PEO/PEG 
matrix (Sako et al., 1996). No attempts have been made using any other drugs with 
different solubilities (Kojima et al., 2008). In addition, as can be seen in Table 1.1, 
very few studies have been carried out with PEO and electrolytes, although the 
studies carried out have proven to be successful, thus encouraging further research 
in this arena. The lack of studies attempting to achieve controlled drug delivery of 
hydrophilic drugs has provided us with motivation to use a drug of this nature but we 
have combined it with a PEO-electrolyte combination in order to control drug delivery. 
 
The fact that polymers can be manipulated by interactions with ions means that their 
physicochemical and mechanical properties can be modified. If these properties are 
altered, it may be possible to change the processes of drug diffusion, dissolution and 
hence delivery.  
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Table 1.1 Interactions of PEO with various ions 
Ion character Specific ions Reference 
Monovalent Cations Na
+
, K
+
 (Beaudoin et al., 2002) 
Divalent Cations Ca
2+
, Mg
2+
 (Beaudoin et al., 2002) 
Counterions of dodecyl 
sulphates 
 
Li
+
 (LDS), Na
+
, (NaDS), TMA
+
, (TMADS) 
 
(Froehner et al.,1998) 
1
9
9
8
)
 
s
s
s
a
a
a
l
a
l
a
l
a
a
l
a
l
,
1
9
9
8
)
 
1
9
9
8
) 
Polymer/surfactant 
interactions 
 
 
PEO/NaDS + H2O solution 
PEO/NaDS + H2O + ethanol (Short) 
PEO/NaDS + ethanol (Short chain)  
PEO/NaDS + n-octanol (Long chain alcohol) 
(Smitter et al., 2001) 
2
0
0
1
) 
Polymer with natural rubber 
 
 
 
 
(PEO1000 – (BSLi)2) + NR (natural rubber) at 
40%wt 
(PEO1000 – (BSLi)2) + NR (natural rubber) at 
10%wt 
(PEO1000 – ImB) + NR (natural rubber) at 40%wt 
(PEO1000 – ImB) + NR (natural rubber) at 10%wt 
(Yoshizawa et al., 
2000) 
 
 
 
Ionic salts Ca
2+
, Ni
2+
, Co
2+
, Zn
2+
, Pb
2+
 (Huq et al., 1988) 
Active chitosan salt blends 
with water solution of PEO 
and PVA 
Active chitosan salt blends with water solution of 
PEO and Polyvinyl Alcohol (PVA) 
(Mucha, 1998) 
(PEO) – NaI complexes with 
different Na:O ratios 
(PEO) – NaI complexes with different Na:O ratios 
(Mohamed et al., 
1997) 
Sodium Nitrate NaNO3 
(Sreekanth et al., 
1999) 
Cation K2TiF6  (Huguenin et al., 2001) 
 
Key: 
LDS:  Lithium Dodecyl Sulfate 
NaDS:  Sodium Dodecyl Sulfate 
TMADS:  Tetramethylammonium Dodecyl Sulfate 
LiBS:  Lithium benzene sulfonate 
ImB:  Imidazolium Bromide 
NaI:  Sodium Iodide 
NaNO3:  Sodium Nitrate 
K2TiF6:  Potassium Hexafluortitanate complex 
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 1.5 Aim and Objectives of this Study 
The aim of this study was to modify the physicochemical and physicomechanical 
properties of PEO in order to influence the hydrodynamic diffusion of its three-
dimensional network. Hence, through such alteration, it was envisaged that if drug is 
loaded into its PEO matrix, its solubility and dissolution can be regulated in order to 
achieve zero-order influx of dissolution medium. The interaction between PEO and 
electrolytes may allow for precipitation of ions on the polymer backbone. This would 
lead to the attraction of water molecules to the ions. As a result, this would cause 
dehydration of the polymer matrix, hence minimising its mobility and relaxation. To 
accomplish this aim, the following objectives are outlined: 
 
i. To undertake preliminary investigations that would allow for understanding of the 
interactions between PEO and various anionic and cationic entities. 
ii. To statistically evaluate the significance of the interactions between the 
independent variables such as polymer concentration, polymer blends and 
molecular weights on the dependent variables using an Analysis of Variance (by 
stepwise forward and backward regression) based on Design of Experiments.  
iii. To assess the surface morphology of the modified PEO. 
iv. To investigate any changes in the micromechanical properties of the modified 
PEO such as the materials resilience, fracture force and work performed. 
v. To compare the molecular structural transitions of altered with unaltered PEO. 
vi. To assess the thermal compatibility of the altered PEO against unaltered PEO. 
vii. To compare the drug dissolution characteristics from native and modified PEO 
delivery systems using a model highly water soluble drug. 
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1.6 Overview of this Research Report 
 
Section 1 provides a concise literature survey of PEO drug delivery systems in 
addition to an overview of the rationale and the motivation for this study. It describes 
the need for specialized drug delivery systems utilizing polymers, in particular PEO. 
The properties of PEO are described that make it ideal for manipulation and use in 
diverse biomedical applications and its ability to control the release of drugs into the 
body. Various PEO-based drug delivery systems and their advantages and uses are 
discussed. The limitations of in vitro and in vivo studies are also outlined via 
reference to previous studies performed with PEO. Numerous studies that report the 
use of high and low molecular weight PEO plus combination with hydrophilic and 
hydrophobic drugs are also reviewed and critiqued. This section concludes with 
describing the modification of PEO by ionic interaction and with the aims and 
objectives of the current study. 
 
In Section 2, the synthesis of the PEO-electrolyte combinations and the outcomes of 
the study are explicated. The formulation strategy used in synthesizing the PEO-
electrolyte combinations and the variables employed to optimize the tablet 
formulation process using a Box-Behnken statistical experimental design are 
described. The PEO-electrolyte combinations were assessed for surface morphology, 
textural profiling, molecular structural transitions, thermal compatibility and in vitro 
drug release from the modified PEO-based tablet matrices. The methods for these 
various assessments are also described.  
 
    21 
In Section 3, the results of this investigation are illustrated and discussed. These 
include morphology, textural profiling, molecular structural transitions, thermal 
compatibility analysis, in vitro drug release and optimum drug release profile.  
 
Section 4 provides a conclusion to the key findings of this study and describes the 
recommendations for further enhancement of the PEO-electrolyte combinations in 
order to further control drug release for future potential as a novel drug delivery 
system. 
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SECTION 2 
DEVELOPMENT OF THE POLYETHYLENE OXIDE-ELECTROLYTE 
COMBINATIONS AND SUBSEQUENT TABLET MATRICES 
 
2.1 Introduction 
 
This section aims to describe the development of the salted-out polyethylene oxide 
(PEO)-electrolyte combinations. The challenge associated with developing the PEO-
electrolyte combinations was in selecting the correct PEO grade and electrolytes. 
Among desirable features, the PEO grade selected should possess inherent 
physicochemical characteristics that facilitated the attainment of a high gel-state 
upon swelling, ability to maintain a constant gel layer integrity over a prolonged 
period of time and hence reduce the erosion rate, and complete dissolution of PEO 
upon exhaustion of drug release from a tablet matrix (Pillay, Fassihi, 1999). PEO has 
been used for controlled-release matrix systems of hydrophobic as well as 
hydrophilic drugs. PEO is a tough, crystalline polymer at room temperature, and the 
glass transition temperature decreases from 245-253.8°C with increasing molecular 
mass. It is non-toxic, non-irritant, and does not generate residue, sediment, or 
vaporous elements. These properties indicate that PEO grades are sufficiently stable 
to work with. Since PEO is non-ionic, no interaction between the drug and PEO is 
expected (Dharwan et al., 2005).  
 
The release rate of drug from biodegradable polymers can be controlled by a number 
of factors, such as the biodegradation kinetics of the polymer, physicochemical 
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properties of the polymer and drug, thermodynamic compatibility between the 
polymer and drug, and the shape of the device. The drug-release mechanism is 
controlled by several variables in a dynamic process (Dharwan et al., 2005). 
 
Studies by Pillay and Fassihi (1999) have indicated that where previous drug delivery 
systems relied exclusively on the physical characteristics of the excipients/polymers 
to provide controlled release, reactions between pharmaceutically acceptable 
electrolytes or acids and drug can form a ‘metamorphic scaffold’ for the purpose of 
providing integrity to a single, hydrophilic polymer system (Pillay and Fassihi, 1999). 
The metamorphic scaffold controls the rate of intragel swelling and the diffusion of 
drug. Simple in design, this system has been shown to produce pH-independent, 
near zero-order dissolution profiles of up to 24 hours (Pillay and Fassihi, 1999). In 
this study, a Box-Behnken statistical, experimental design was employed to derive 
the 36 experimental formulation combinations from selected independent and 
dependant formulation variables. 
 
2.2 Materials and Methods 
 
2.2.1 Materials 
Polyethylene oxide (Polyox® WSR303 NF, Mw=7x106g/mol) was purchased from 
Union Carbide Corp. (Danbury, CT, USA). The following electrolytes were combined 
with PEO: zinc carbonate (ZnCO3), ammonium sulphate [(NH4)2SO4], sodium 
phosphate (Na3PO4), sodium carbonate (Na2CO3) and di-potassium hydrogen 
orthophosphate (K2HPO4). The model drug used was diphenhydramine HCl 
(solubility is greater than or equal to 100mg/mL at 21.5˚C). 
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2.2.2 Methods 
2.2.2.1 Preliminary investigations 
Various compounds were selected to interact with PEO. These compounds were as 
follows: ZnCO3, (NH4)2SO4, Na3PO4, Na2CO3 and K2HPO4. The ether oxygen of PEO 
reacts with the positive ions of the selected compounds, e.g.: Na+, K+, Zn2+ and 
(NH4)
2+. Though direct evidence is not yet available, it is believed acid-base 
coordination between the cations and the oxygen of the ether of PEO comprises the 
major interaction. The interactions between PEO and each of the compounds are 
outlined hereunder: 
PEO + ZnCO3    PEO: ZnCO3 
PEO + (NH4)2SO4    PEO: (NH4)2SO4 
PEO + Na3PO4    PEO: Na3PO4 
PEO + Na2CO3    PEO: Na2CO3 
PEO + K2HPO4    PEO: K2HPO4 
 
2.2.2.2 Building the experimental design 
Design of Experiments (DoE) is an efficient statistical tool for planning formulations 
so that data obtained can be analyzed to yield valid and objective conclusions. The 
primary objective of this study was to modify the physicochemical and 
physicomechanical properties of PEO so that we could induce zero-order influx of 
water and efflux of drug.  
 
A Box-Behnken statistical design composed of 5 factors, 36 random experimental 
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runs and 5 centre-points was built using Minitab® software release version 14 
(Minitab® Inc., PA, USA). A series of 36 different formulations were carefully chosen 
from a fractional factorial design to formulate and analyze. The combinations were 
selected so as to give the maximum effective interpretation of results without using 
an excessive number of experiments which would have been 180 in total. Five 
different process variables namely ZnCO3, (NH4)2SO4, Na3PO4, Na2CO3 and K2HPO4 
were optimized using this design and were varied in a series of 36 different 
formulations. The effect of the variations within each formulation on fracture force, 
resilience and work performed was observed.  
 
2.3 Formulation of the Polyethylene Oxide-Electrolyte Combinations  
For each of the 36 solutions, 2g of PEO was dissolved in 100mL distilled water. 
Various combinations of ZnCO3, (NH4)2SO4, Na3PO4, Na2CO3 and K2HPO4 as listed 
in Table 2.1 were weighed out, each combination being a total of 2g. The 
concentration of the PEO to electrolyte was maintained at a constant 1:1 ratio by 
utilizing 2g of PEO and 2g of electrolyte. The 2g of electrolyte was then weighed, 
crushed using a mortar and pestle and then added to the PEO solution. Table 2.1 
indicates the quantities of electrolyte and PEO for each sample. Each solution was 
then stirred using a magnetic stirrer for 30 minutes on a medium frequency. After the 
stirring process, the 36 solutions were covered with Parafilm® M (Pechiney Plastic 
Packaging Company, Chicago, USA) and cured in a dark area for 24 hours. 
Thereafter, the PEO-electrolyte combinations were filtered and washed (3x100mL) 
with de-ionized water and placed on petri dishes to dry. Each PEO-electrolyte 
sample was then dried under the extractor at 30°C for 1 week. The samples were 
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then removed and microscopically analyzed and subjected to textural analysis. Table 
2.1 depicts the independent formulation variables tested in the 36 experiments. The 
Box-Behnken statistical design described in Section 2.2.2.1 was employed to 
optimize and evaluate the main effects and interaction effects of the sample drug 
(diphenhydramine HCl) in combination with the PEO-electrolytes on drug delivery.  
The concentrations of the independent variables which were used to prepare the 
design generated experimental formulations are illustrated in Table 2.1. The 
dependent variables included fracture force, resilience, work performed and 
cumulative percentage drug release. 
 
2.4 Assessment of the Surface Morphology of the Polyethylene Oxide-
Electrolyte Combinations 
The external morphology of the 36 polymer-electrolyte combinations was visually 
characterized according to texture and color. Each sample was visually analyzed and 
photographed using Analysis® software on a digital microscope (Olympus, USA).  
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Table 2.1: Box-Behnken design for synthesis of the PEO-electrolyte combinations 
 
 
No: ZnCO3 (NH4)2SO4 Na3PO4 Na2CO3 
and 
(K2HPO4)  
ZnCO3 PEO(g) Electrolyte(g) 
1 0 16.667 0 16.667 16.667 2  0.667 
2 0 0 25 0 25 2  1.000 
3 0 12.5 12.5 12.5 12.5 2  0.500 
4 5 5 5 30 5 2  0.2/1.2 
5 16.667 0 16.667 0 16.667 2  0.667 
6 16.667 16.667 0 0 16.667 2  0.667 
7 16.667 0 16.667 16.667 0 2  0.667 
8 10 10 10 10 10 2  0.400 
9 12.5 0 12.5 12.5 12.5 2  0.500 
10 0 25 0 25 0 2  1.000 
11 25 0 0 0 25 2  1.000 
12 25 0 25 0 0 2  1.000 
13 0 16.667 16.667 0 16.667 2  0.667 
14 0 16.667 16.667 16.667 0 2  0.667 
15 0 25 25 0 0 2  1.000 
16 16.667 0 0 16.667 16.667 2  0.667 
17 12.5 12.5 0 12.5 12.5 2  0.500 
18 12.5 12.5 12.5 0 12.5 2  0.500 
19 16.667 16.667 16.667 0 0 2  0.667 
20 25 0 0 25 0 2  1.000 
21 0 0 0 50 0 2  2.000 
22 16.667 16.667 0 16.667 0 2  0.667 
23 30 5 5 5 5 2  0.2/1.2 
24 0 0 16.667 16.667 16.667 2  0.667 
25 5 5 5 5 30 2  0.2/1.2 
26 0 50 0 0 0 2  2.000 
27 0 0 0 25 25 2  1.000 
28 0 0 0 0 50 2  2.000 
29 5 5 30 5 5 2  0.2/1.2 
30 5 30 5 5 5 2  0.2/1.2 
31 0 0 25 25 0 2  1.000 
32 0 0 50 0 0 2  2.000 
33 0 25 0 0 25 2  1.000 
34 25 25 0 0 0 2  1.000 
35 12.5 12.5 12.5 12.5 0 2  0.500 
36 50 0 0 0 0 2  2.000 
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2.5 Textural Profile Analysis  
A calibrated Texture Analyzer (TA.XTplus, Stable Microsystems, Godalming, Surrey, 
United Kingdom) fitted with a steel probe (2mm diameter) was employed in the 
determination of the textural characteristics of the 36 polymer-electrolyte 
combinations. The parameter settings employed in this analysis are outlined in Table 
2.2. Combinations were analyzed for resilience (N/s), energy absorbed (J) and 
fracture force (N/mm). 
 
2.5.1 Determination of resilience, energy absorbed and fracture force of the 
polyethylene oxide-electrolyte combinations 
Resilience refers to deformation upon application of a force. Figure 2.1a depicts an 
example of a force-time profile for the determination of the resilience (N/s). It was 
calculated as the ratio of the areas under the compression and decompression curve. 
The energy absorbed (J) was determined by calculating the area under the curve 
(AUCFD) of a force–distance profile as depicted in Figure 2.1b. The fracture force 
was calculated as the point at which the material starts to yield, indicated by an 
indentation in the force-distance profile as depicted in Figure 2.1c      
 
Table 2.2: Textural parameter settings employed in the determination of resilience, energy 
absorbed and fracture force 
Parameters Settings 
 
Pre-test speed 
Test Speed 
Post-Test Speed 
Compression Force 
Load Cell 
Trigger Type 
Trigger Force 
Return Distance 
1mm/sec 
0.5mm/sec 
1mm/sec 
40N 
50kg 
Auto 
0.5 N 
20mm 
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Figure 2.1: Typical profiles for the determination of a) resilience, b) energy absorbed and c) 
fracture force of the PEO-electrolyte combination (50% Na3PO4, 50% K2HPO4). 
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2.6 Assessment of the Molecular Structural Transition of the Salted-Out 
Polyethylene Oxide -Electrolyte Combinations 
A Fourier Transform Infrared (FTIR) spectrometer (PerkinElmer Spectrum One with 
Spectrum V5.00 software, PerkinElmer Instruments, CT, USA) was used to detect 
the vibrational characteristics of chemical functional groups in each of the salted-out 
PEO-electrolyte combinations in response to infrared light interactions. The infrared 
signal after interaction with the sample is uniquely characteristic for a sample. 
Interferograms are translated via the mathematical technique of Fourier 
Transformation before being presented as an infrared spectrum, which plots 
transmittance versus wavenumber. A typical plot for each of the salted-out PEO-
electrolyte combinations was obtained and compared to the plot of native PEO. A 
profile showing the transmittance of the individual polymer, PEO was produced as 
well as profiles of the salted-out PEO-electrolyte combinations in order to determine 
any potential interactions. A sample of the blended preparation was used in the 
platinum crucible to generate the resulting percentage transmittance profile 
(Stancanelli et al., 2008; da Silver-Junior et al., 2009). 
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2.7 Thermal Compatibility Analysis of the Salted-Out Polyethylene Oxide -
Electrolyte Combinations 
The differential scanning calorimeter (DSC) can be used for determining different 
thermal properties of a polymeric material such as the glass transition temperature 
Tg, melting temperature Tm, enthalpy of melting and crystallization and the oxidative 
induction time (OIT). The sample and the reference are heated in the same chamber 
(the oven) according to a program which provides the information about the 
temperature (combination of isothermal and dynamic segments) and the reaction gas 
(nitrogen for inert and oxygen for oxidative atmosphere). Two separate heat sensors 
continuously read the temperature of the sample and the reference crucible. In 
absence of a thermal event the temperatures of the sample and the reference should 
be the same according to the temperature program. 
 
In case of a thermal event, e.g. melting, the temperature of the sample deviates from 
that given in the temperature program (the temperature of the reference). Heat 
(electric effect) is supplied to or withdrawn from the sample in order to correct for this 
deviation. The deviation in the thermogram from the base-line supplies information 
about the thermal behaviour of the material in the temperature program range. 
Thermograms were captured using a Mettler-Toledo TC15, TA Controller System 
(Switzerland) with a DSC instrument (Mettler DSC 20, Mettler-Toledo AG, 
Switzerland). An indium calibration was performed for the analyses. 10mg to 20mg 
samples were transferred to aluminium pans and sealed immediately. The heating 
rate was 5 C per minute and the temperature range captured was 20-300°C.  
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The polymer, PEO was individually analyzed in order to obtain a base thermogram. 
Thermograms of all the salted-out PEO-electrolyte combinations were then obtained 
and compared to the base thermogram in order to note whether any physical 
interactions had occurred. Potential crosslinking between the PEO and the 
electrolytes were also noted in order to detect if the crosslinking had any 
physicochemical interaction when the electrolytes and PEO were physically 
combined.  
 
2.8 UV Spectrophotometry Analysis of Diphenhydramine HCl Content  
 
2.8.1 Preparation of calibration curves and assay procedure  
Stock solutions were prepared by separately dissolving variable accurately weighed 
quantities of diphenhydramine HCl in 100mL simulated intestinal fluid (SIF) buffer 
(pH 6.8; 37°C).The following concentrations were prepared: 0.005mg/mL, 
0.004mg/mL, 0.003mg/mL and 0.002mg/mL. The UV absorbance of each standard 
solution was determined at the maximum wavelength of absorption (λmax) of 254nm 
for diphenhydramine HCl. SIF was used as the reference. No other components 
absorbed in this range. A calibration curve (R2=0.99) was constructed as depicted in 
Figure 2.2. Simulated intestinal fluid was prepared according to the USP method. 
The pH of the test solution used was 6.8. 
 
 
      33 
 
Figure 2.2: Calibration curve of diphenhydramine HCl in simulated intestinal fluid (pH 6.8; 
37°C). 
 
2.9 In Vitro Drug Release Studies 
2.9.1 Dissolution of the salted-out polyethylene oxide-electrolyte combinations 
In vitro drug release studies were performed on the eight salted-out PEO-electrolyte 
combinations. Each salted-out PEO-electrolyte combination was combined with the 
drug, diphenhydramine HCl to form a 500mg tablet (diameter=13mm, 
thickness=5mm, friability<1%; N=5) on a Carver Press set at 3 tons. Each tablet was 
placed in a calibrated six-station dissolution testing apparatus (Caleva Dissolution 
Apparatus, model 7ST) using a USP25 rotating paddle method at 50rpm with 900mL 
of simulated intestinal fluid (pH 6.8; 37°C).  These studies were performed at specific 
time intervals over a period of 10 hours. 5ml of sample was withdrawn and replaced 
with 5ml of buffer solution. Combinations were analyzed by ultraviolet spectroscopy 
(Specord 40, Analytik Jena, AG) at 254nm.  
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SECTION 3 
RESULTS AND DISCUSSION 
 
3.1 Morphology and Yield of the Polyethylene Oxide-Electrolyte Combinations 
The electrolytes appeared to be dispersed evenly within each of the PEO 
formulations. The combinations visually appeared white in color and were 
predominantly linear in shape. There appeared to be some variations in the 
dimensions and the darkness of the PEO-electrolyte combinations between the 
different formulations. This may be due to the different electrolytes and varying the 
concentrations of electrolytes used in each formulation. The texture of the PEO-
electrolyte combinations appeared porous since each formulation was exposed to a 
24 hour period of drying. The 36 formulations were then subjected to textural 
analysis, after which only the salted-out PEO samples were subjected to further 
testing. These tests included FTIR analysis, DSC analysis and dissolution studies. It 
was visually observed that none of the eight salted-out formulations disintegrated in 
simulated intestinal media, pH 6.8 demonstrating that the concentration ratio and 
type of polymers used in the dosage form played a vital role in retaining the dosage 
form intact. The morphology of the PEO-electrolyte combinations is depicted in 
Figure 3.1 (1-36) and the descriptions are tabulated in Table 3.1 
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Sample 1 Sample 2 Sample 3 Sample 4 Sample 5 Sample 6 
      
Sample 7 Sample 8 Sample 9 Sample 10 Sample 11 Sample 12 
      
Sample 13 Sample 14 Sample 15 Sample 16 Sample 17 Sample 18 
      
Sample 19 Sample 20 Sample 21 Sample 22 Sample 23 Sample 24 
      
Sample 25 Sample 26 Sample 27 Sample 28 Sample 29 Sample 30 
      
Sample 31 Sample 32 Sample 33 Sample 34 Sample 35 Sample 36 
Figure 3.1: Morphology of the PEO-electrolyte combinations (1-36). 
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Table 3.1: Description of the PEO-electrolyte combinations (1-36) 
Sample Number Texture 
Salted-out (SO) or Non  
Salted-Out (NSO) 
1 Sticky and Clumpy NSO 
2 Fine Powder NSO 
3 Fine Powder NSO 
4 Lumpy – formed a sticky lump NSO 
5 Powder NSO 
6 Powder NSO 
7 Paper like – cannot be powdered SO 
8 Powder NSO 
9 Gel-like – cannot be powdered SO 
10 Powder NSO 
11 Cannot be Powdered SO 
12 Powder NSO 
13 Powder NSO 
14 Powder NSO 
15 Powder NSO 
16 Cannot be Powdered SO 
17 Cannot be Powdered SO 
18 Powder NSO 
19 Powder NSO 
20 Powder NSO 
21 Powder NSO 
22 Cannot be Powdered SO 
23 Powder NSO 
24 Powder NSO 
25 Powder NSO 
26 Powder NSO 
27 Partially Powdered NSO 
28 Powder NSO 
29 Powder NSO 
30 Cannot be Powdered SO 
31 Partially Powdered NSO 
32 Partially Powdered NSO 
33 Partially Powdered NSO 
34 Powder NSO 
35 Powder NSO 
36 Cannot be Powdered SO 
         37 
Table 3.2: Textural profiling results of the salted-out and non salted-out PEO combinations 
  
 
ZnCO3 (NH4)2SO4 Na3PO4 Na2CO3  K2HPO4 resilience  
N/s 
 
 
fracture force  
N/mm 
 
 
work performed 
J 
 
 
1 0 16.667 0 16.667 16.667 4.722 18.511 0.025 
2 0 0 25 0 25 0.746 38.461 0.203 
3 0 12.5 12.5 12.5 12.5 2.573 102.4 2.385 
4 5 5 5 30 5 1.106 78.452 2.568 
5 16.667 0 16.667 0 16.667 2.606 112.554 3.249 
6 16.667 16.667 0 0 16.667 1.104 39.845 0.847 
7 16.667 0 16.667 16.667 0 4.125 42.049 4.104 
8 10 10 10 10 10 0.621 48.264 0.319 
9 12.5 0 12.5 12.5 12.5 0.572 28.857 0.098 
10 0 25 0 25 0 4.235 56.02 2.194 
11 25 0 0 0 25 1.973 69.155 3.469 
12 25 0 25 0 0 1.217 52.156 0.977 
13 0 16.667 16.667 0 16.667 2.156 79.971 2.057 
14 0 16.667 16.667 16.667 0 3.536 32.334 1.194 
15 0 25 25 0 0 4.013 135.09 3.261 
16 16.667 0 0 16.667 16.667 0.527 39.218 0.131 
17 12.5 12.5 0 12.5 12.5 2.771 115.316 2.791 
18 12.5 12.5 12.5 0 12.5 3.542 85.348 2.22 
19 16.667 16.667 16.667 0 0 1.438 39.204 0.762 
20 25 0 0 25 0 2.293 113.512 0.254 
21 0 0 0 50 0 1.3 70.208 0.218 
22 16.667 16.667 0 16.667 0 1.845 78.462 0.728 
23 30 5 5 5 5 3.355 96.708 1.302 
24 0 0 16.667 16.667 16.667 0.408 24.343 0.064 
25 5 5 5 5 30 0.758 26.786 0.337 
26 0 50 0 0 0 0.676 44.811 0.074 
27 0 0 0 25 25 2.897 57.053 0.711 
28 0 0 0 0 50 4.235 145.665 3.508 
29 5 5 30 5 5 0.303 56.547 0.56 
30 5 30 5 5 5 3.245 100.917 0.213 
31 0 0 25 25 0 0.689 39.36 0.019 
32 0 0 50 0 0 0.462 53.875 0.134 
33 0 25 0 0 25 0.954 65.36 0.253 
34 25 25 0 0 0 1.953 74.249 1.21 
35 12.5 12.5 12.5 12.5 0 2.456 121.23 0.286 
36 50 0 0 0 0 0.521 37.286 0.294 
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3.2 Response Surface Plots Depicting the Effect of Electrolyte Type on the 
Dependant Formulation Variables 
The non-linear surface response plots of the salted-out electrolyte combinations 
depicting the effect of the electrolyte type on the dependant formulation variables 
have been outlined and discussed. The salted-out electrolyte combinations listed 
below have displayed a linear effect and are hence not discussed. 
 combination salted-out with Na2CO3 and K2HPO4 
 combination salted-out with (NH4)2SO4 and K2HPO4 
 combination salted-out with (NH4)2SO4 and Na2CO3 
 combination salted-out with (NH4)2SO4 and Na3PO4 
 combination salted-out with ZnCO3 and K2HPO4 
 combination salted-out with ZnCO3 and Na2CO3 
 combination salted-out with ZnCO3 and Na3PO4 
 
3.2.1 Effect on resilience of the salted-out polyethylene oxide-electrolyte 
combinations 
The combination salted-out with a blend of ZnCO3 and (NH4)2SO4 resulted in a rapid 
decrease in resilience (Figure 3.2.1a) due to the influence of (NH4)2SO4 whilst the 
formulation salted-out with a combination of Na3PO4 and K2HPO4 resulted in an initial 
decrease followed by an increase in resilience (Figure 3.2.1b) due to the influence of 
K2HPO4. Interestingly though, only one of the salted-out combinations resulted in an 
increase in resilience. This was due to the presence of Na2CO3 in the formulation 
salted-out with a blend of Na3PO4 and Na2CO3 (Figure 3.2.1c). We can hence deduce 
that only Na2CO3 results in an increase in resilience from all the combinations.  
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Figure 3.2.1(a-c): Response surface plots depicting the effects of electrolyte types on the 
resilience of the salted-out non-linear PEO combinations. 
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3.2.2 Effect on fracture force of the salted-out polyethylene oxide-electrolyte 
combinations 
The presence of ZnCO3 did not have much of an impact on the fracture force but the 
inclusion of (NH4)2SO4 significantly decreased the fracture force in Figure 3.2.2a. In 
Figures 3.2.2b and c, an increase in Na3PO4 levels resulted in a rapid decrease in 
fracture force whilst an increase in the K2HPO4 and Na2CO3 (Figures 3.2.2b and c) 
levels result in an increase in fracture force. We can hence deduce that an increase in 
Na3PO4 concentration decreases fracture force and is not influenced by the presence 
of other electrolytes.   
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Figure 3.2.2(a-c): Response surface plots depicting the effects of electrolyte types on the 
   fracture force of the salted-out non-linear PEO combinations. 
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3.2.3 Effect on work performed of the salted-out polyethylene oxide-electrolyte 
combinations 
Higher concentrations of ZnCO3 resulted in an increase in work performed whilst 
higher concentrations of (NH4)2SO4 resulted in a decrease in work performed (Figure 
3.2.3a). However, this combination showed a less dramatic increase in work 
performed compared to the combinations without the presence of (NH4)2SO4. 
Combinations salted-out with a blend of Na3PO4 and K2HPO4 (Figure 3.2.3b) or 
Na3PO4 and Na2CO3 (Figure 3.2.3c) all resulted in an increase in work performed with 
increasing electrolyte concentration. We can thus deduce that the presence of 
(NH4)2SO4 decreased the work performed indicating that it is a weaker electrolyte and 
allows for very little crosslinking with PEO whilst all the other electrolytes result in an 
increase in work performed.  
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Figure 3.2.3(a-c): Response surface plots depicting the effects of electrolyte types on the 
work performed of the salted-out non-linear PEO combinations. 
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3.3 Assessment of the molecular structural transition of the salted-out 
polyethylene oxide-electrolyte combinations 
A FTIR spectrometer was used to detect the vibration characteristics of the chemical 
functional groups in the salted-out PEO-electrolyte combinations in response to 
infrared light interactions. A typical plot showing the transmittance of the polymer, 
PEO alone was first obtained. Thereafter, profiles of all the salted-out PEO-electrolyte 
combinations were obtained and compared to the profile of the original PEO sample. 
 
Table 3.3 lists the transmittance peaks in the fingerprint region of 650-3500cm-1 for 
PEO and the PEO-electrolyte combinations. Peaks that were not present in the native 
PEO sample were identified. All the PEO-electrolyte combinations produced new 
peaks in the region of 650-750cm-1 whilst only Figure 3.3.9 produced a new peak at 
776.32cm-1. Figure 3.3.7 produced a new peak at 876.07cm-1 whilst Figures 3.3.4, 
3.3.6 and 3.3.9 produced new peaks in the region of 1000–1050cm-1. Figure 3.3.3 
and Figure 3.3.8 produced an extra peak in the region of 1400–1450cm-1 and Figure 
3.3.5. and 3.3.6 produced extra peaks in the region of 1500–1650cm-1. Figures 3.3.2, 
3.3.3, 3.3.5 and 3.3.8 produced extra peaks in the region of 1650–1700cm-1 and 
Figures 3.3.2, 3.3.6, 3.3.7, 3.3.8 and 3.3.9 produced an extra peak in the region of 
2050–2300cm-1. All the combinations produced extra peaks in the region of 3000–
3500cm-1. From the data it was not possible to ascertain whether these peaks are due 
to an interaction between the electrolytes and PEO or are part of the fingerprint of 
PEO present in the combinations. Further studies into possible physical interactions 
were undertaken via differential scanning calorimetry reported later in this section. 
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Table 3.3: Wavenumbers for each of the salted-out polyethylene oxide-electrolyte combinations 
Wavenumbers 
Figure 
2.8.1 
Native 
PEO  
Figure 
2.8.2 
Figure 
2.8.3 
Figure 
2.8.4 
Figure 
2.8.5 
Figure 
2.8.6 
Figure 
2.8.7 
Figure 
2.8.8 
Figure 
2.8.9 
650-700 
 
685.96 685.99 
 
682.41 
    
700-750 
 
708.41, 
738.81  
707.68, 
740.58 
708.28, 
741.98 
708.32, 
739.13 
707.64, 
738.38 
707.09 706.92 
750-800 
        
776.32 
800-850 840.81 833.88 840.92 840.96 841.79 840.8 833.29 841.64 831.29 
850-900 
      
876.07 
  
900-950 946.32 
        
950-1000 960.75 960.9 960.42 960.36 
 
960.51 960.48 
961.45, 
981.70 
961.56 
1000-1050 
   
1019.94 
 
1018.95 
  
1045.07 
1050-1100 1059.31 
1059.43, 
1099.86 
1094.8 
     
1060.56 
1100-1150 1144.61 1145.7 1145.42 1144.62 
1100.05, 
1145.31 
1144.76 
  
1102.63,
1145.91 
1200-1250 1241.35 1241.6 1241.57 1241.59 1241.82 1241.58 1241.58 1241.7 
 
1250-1300 1279.13 1279.9 1279.15 1279.69 1280.6 1279.51 1279.83 1280.06 1280.73 
1300-1350 1341.69 1341.6 1341.55 1341.67 1342.24 1341.65 1341.61 1342.04 
 
1350-1400 1359.91 
 
1359.82 1359.9 
1359.77, 
1389.53 
1359.88 1359.6 1360.18 1380.72 
1400-1450 
  
1413.15 
    
1428.8 
 
1450-1500 1466.79 1499.8 1466.49 
1466.87,
1499.44 
1467.62 1466.91 
1467.01,
1499.59   
1500-1550 
    
1501.02 1501.36 
   
1600-1650 
     
1648.02 
   
1650-1700 
 
1679.1 1684.2 
 
1676.92 
  
1667.15 
 
1850-1900 1980.83 1979.4 1979.34 1979.44 
 
1979.89 
   
2050-2100 
 
2050.9 
    
2090.5 2050.56 2085.78 
2150-2200 
     
2164.79 2163.06 
  
2250-2300 
 
2283 
       
2850-2900 2878.29 2884.3 2879.14 2882.32 2884.11 2882.24 2879.01 2883.14 2883.9 
3000-3100 
       
3045.29 
 
3100-3200 
       
3195.46 
 
3200-3300 
 
3290.9 
  
3289.72 
 
3292.82 
 
3294.08 
3300-3400 
   
3308.62 
 
3306.83 
   
3400-3500 
  
3460.21 
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Figure 3.3.1: A typical FTIR plot of native PEO 303. 
 
 
 
 
Figure 3.3.2: A typical FTIR plot of the salted-out sample 7 showing the combination of PEO 303, ZnCO3, 
Na3PO4 and Na2CO3. 
 
 
 
 
Figure 3.3.3: A typical FTIR plot of the salted-out sample 9 showing the combination of PEO 303, ZnCO3, 
Na3PO4 and K2HPO4. 
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Figure 3.3.4: A typical FTIR plot of the salted-out sample 11 showing the combination of PEO 303, 
ZnCO3 and K2HPO4. 
 
 
 
Figure 3.3.5: A typical FTIR plot of the salted-out sample 16 showing the combination of PEO 303, 
ZnCO3, Na2CO3 and K2HPO4. 
 
 
 
 
Figure 3.3.6: A typical FTIR plot of the salted-out sample 17 showing the combination of PEO 303, 
ZnCO3, (NH4)2SO4, Na2CO3 and K2HPO4. 
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Figure 3.3.7: A typical FTIR plot of the salted-out sample 22 showing the combination of PEO 303, 
ZnCO3, (NH4)2SO4 and Na2CO3. 
 
 
 
 
Figure 3.3.8: A typical FTIR plot of the salted-out sample 30 showing the combination of PEO 303, 
ZnCO3, (NH4)2SO4, Na3PO4, Na2CO3 and K2HPO4. 
 
 
 
 
Figure 3.3.9: A typical FTIR plot of the salted-out sample 36 showing the combination of PEO 303 and 
ZnCO3. 
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3.4 Thermal compatibility analysis of the salted-out polyethylene oxide-electrolyte 
combinations 
PEO is a thermoplastic semi-crystalline polymer with a flexible chemical structure. It has a 
melting point ranging from 60°C-75°C and a glass transition temperature of -67°C. DSC testing 
was carried out on all the salted-out combinations and each thermogram was analyzed in terms 
of glass transition and melting point. For each thermogram carried out on all the salted-out 
combinations, the integral onset and end set temperatures were determined for each significant 
thermal event. The mean values are shown in Table 3.4 
 
Table 3.4: Mean integral, onset and endset temperature values for each of the salted-out 
combinations. 
Sample 
Number 
Mean sample 
mass 
Mean integral 
(mJ±SD) (N=2) 
Mean onset 
temperature 
(°C±SD) (N=2) 
Mean endset 
temperature 
(°C±SD) (N=2) 
7 13.3 751.07 40.32 65.52 
36 16 27.12 42.40 69.83 
9 11.4 178.83 39.70 69.10 
11 12.8 400.12 43.08 69.26 
17 15.5 -31.79 30.04 48.78 
30 16.2 134.22 42.76 60.97 
22 15.2 6428.95 164.32 214.64 
16 12.2 8761.71 125.31 194.40 
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Figure 3.4.1: Thermogram of native PEO 303. 
 
 
Figure 3.4.2: Thermogram of the salted-out sample 7 showing the combination of PEO 303, ZnCO3, 
Na3PO4 and Na2CO3. 
 
Figure 3.4.2 depicts the thermogram of the salted-out PEO sample utilizing the electrolytes 
ZnCO3, Na3PO4 and Na2CO3. The first transition occurred at 65.52°C which correlates to the 
melting point of PEO. There is an additional melting point peak at 120°C which could represent 
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the melting point peak of one of the electrolytes. The crystallization peak is present at around 
160°C for PEO. This indicates minimal interaction between PEO and the electrolytes. 
 
 
Figure 3.4.3: Thermogram of the salted-out sample 9 showing the combination of PEO 303, ZnCO3, 
Na3PO4 and K2HPO4. 
 
Figure 3.4.3 depicts the thermogram of the salted-out PEO sample utilizing the electrolytes 
ZnCO3, Na3PO4 and K2HPO4. The first transition occurred at 69.83°C which correlates to the 
melting point of PEO. The crystallization peak which normally occurs at around 190°C for PEO 
is absent. This may indicate some form of an interaction between PEO and the electrolytes.  
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Figure 3.4.4: Thermogram of the salted-out sample 11 showing the combination of PEO 303, ZnCO3 and 
K2HPO4. 
 
Figure 3.4.4 depicts the thermogram of the salted-out PEO sample utilizing the electrolytes, 
ZnCO3 and K2HPO4. The first transition occurred at 69.10°C which correlates to the melting 
point of PEO. There is an additional melting point peak at approximately 110-120°C 
representative of the peak of an additional electrolyte and the crystalline peak which normally 
occurs at approximately 190°C in PEO is absent. The additional peak may account for the peak 
of either ZnCO3 or K2HPO4, and the absence of the crystalline peak could indicate an interaction 
between the electrolytes and PEO.  
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Figure 3.4.5: Thermogram of the salted-out sample 16 showing the combination of PEO 303, ZnCO3, 
Na2CO3 and K2HPO4. 
 
Figure 3.4.5 depicts the thermogram of the salted-out PEO sample utilizing the electrolytes 
ZnCO3, Na2CO3 and K2HPO4. This thermogram is very similar to Figure 3. The first transition 
occurred at 69.26°C which correlates to the melting point of PEO. There are 2 additional melting 
point peaks at approximately 110-120°C and 210°C and the crystalline peak which normally 
occurs at approximately 190°C in PEO is absent. The additional peaks may account for the 
peaks of either electrolytes ZnCO3, Na2CO3 and K2HPO4 and the absence of the crystalline peak 
could indicate an interaction between the electrolytes and PEO.  
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Figure 3.4.6: Thermogram of the salted-out sample 17 showing the combination of PEO 303, ZnCO3, 
(NH4)2SO4, Na2CO3 and K2HPO4. 
 
Figure 3.4.6 depicts the thermogram of the salted-out PEO sample utilizing the electrolytes 
ZnCO3, (NH4)2SO4, Na2CO3 and K2HPO4. The first transition occurred at 48.78°C. There were 
no other peaks present, hence indicating a definite interaction between PEO and the 
electrolytes. This decrease in melting point may suggest that PEO may have transformed its 
structure from its original extended crystallite to a more folded chain crystallite and that no 
crosslinking has occurred.  
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Figure 3.4.7: Thermogram of the salted-out sample 22 showing the combination of PEO 303, ZnCO3, 
(NH4)2SO4 and Na2CO3. 
 
Figure 3.4.7 depicts the thermogram of the salted-out PEO sample utilizing the electrolytes 
ZnCO3, (NH4)2SO4 and Na2CO3. The first transition occurred at 60.97°C which correlates to the 
melting point of PEO. The crystallization peak is present at around 170°C which correlates to 
the crystallization peak for PEO. This indicates minimal interaction between PEO and the 
electrolytes. 
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Figure 3.4.8: Thermogram of the salted out sample 30 showing the combination of PEO 303, ZnCO3, 
(NH4)2SO4, Na3PO4, Na2CO3 and K2HPO4. 
 
Figure 3.4.8 depicts the thermogram of the salted-out PEO sample utilizing the electrolytes 
ZnCO3, (NH4)2SO4, Na3PO4, Na2CO3 and K2HPO4. The first transition occurred at 214.64°C. 
This is an extremely high melting point and indicates that crosslinking has occurred. There are 
no other peaks present.  
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Figure 3.4.9: Thermogram of the salted out sample 36 showing the combination of PEO 303 and ZnCO3. 
 
Figure 3.4.9 depicts the thermogram of the salted-out PEO sample utilizing the electrolyte 
ZnCO3. The first transition occurred at 194.40°C, This thermogram is very similar to that of 
Figure seven with a very high melting point. This may also suggest that crosslinking has 
occurred. From the discussion above we can gauge that the most favorable PEO-electrolyte 
combination would be that of PEO with ZnCO3, (NH4)2SO4, Na3PO4, Na2CO3 and K2HPO4 as it 
is one of the combinations in which crosslinking may have occurred. This formulation is much 
more stable at higher temperatures and thus useful for an extended shelf-life.    
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3.5 In Vitro Drug Release Studies 
Each salted-out PEO-electrolyte combination was combined with the drug, diphenhydramine 
HCl to form a tablet. Each tablet was then subjected to dissolution testing over a 10 hour period 
utilizing a prepared buffer solution at a pH of 6.8. The compositions of each formulation are 
listed in Table 3.5 hereunder. The dissolution profiles for all eight tablets are depicted in Figure 
3.5 (F1 – F8). 
 
Table 3.5: Salted-out formulations and their electrolyte compositions 
Formulation Composition 
1 33.3% ZnCO3, 33.3% Na2CO3 and  33.3% Na3PO4 
2 25% ZnCO3, 25% Na2CO3, 25% Na3PO4 and 25% K2HPO4 
3 50% ZnCO3 and 50% K2HPO4  
4 33.3% ZnCO3, 33.3% Na2CO3 and 33.3% K2HPO4  
5 25% ZnCO3, 25% (NH4)2SO4, 25% Na2CO3 and 25% K2HPO4  
6 33.3% ZnCO3, 33.3% (NH4)2SO4 and 33.3% Na2CO3 
7 10% ZnCO3, 60% (NH4)2SO4, 10% Na2CO3, 10% Na3PO4 and 10% 
K2HPO4  
8 100% ZnCO3 
 
 
Figure 3.5: Dissolution profiles for the eight salted-out PEO-electrolyte tablets (F1 - F8) 
 (standard deviation<0.5% in all cases, N=3). 
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Formulation 1 showed a linear release pattern during the entire 8 hour period. It was 
marked by an initial 40% release of drug during the first hour followed by an a slower 
diffusional drug release phase during the next 2 hours and then a slightly higher but 
steady release rate of Diphenhydramine HCl over the last 4 hours. Formulations 2, 3 
and 4 were marked by an initial 75–85% release of drug during the first hour followed 
by a steady release rate of drug over the next 5 hours. Formulation 5 and 6 showed 
a very similar release pattern. Both formulations showed release rates that were 
biphasic, marked by an initial 50-60% release of drug followed by a slower diffusional 
drug release phase. Formulation 7 and 8 did not show the most favorable drug 
pattern as almost all the drug was released during the first 2 hours. Combinations of 
the aforementioned formulations comprised of different concentrations of electrolytes 
combined with an equivalent concentration of PEO. From our discussion above, we 
can conclude that formulation one was the most favorable formulation as it showed 
one of the best drug release patterns. There was initial slight increase of drug during 
the first hour in order to build up levels of drug in the plasma or appropriate tissue 
followed by a sustained drug release pattern over the next few hours. This may have 
been due to the precipitation of the electrolyte on the PEO backbone leading to the 
attraction of water molecules. As a result this may have caused dehydration of the 
PEO matrix, hence minimizing its mobility and relaxation and thus regulating drug 
release.  
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3.6 Optimum Drug Release Profile 
Minitab® V14 was used to optimize the following parameters: resilience, fracture 
force and work performed. These parameters were selected to provide for the 
qualitative and quantitative kinetic modeling of drug release from the salted-out PEO 
combinations. The major influence is attributable to the type of electrolyte employed 
in the formulation. Optimal responses generated by the inherent optimization function 
of Minitab® are depicted by the plots in Figure 3.6. According to the predictions of the 
statistical design, the optimal sample that would provide a linear drug release profile 
would comprise concentrations of 50% Na2CO3 and 50% K2HPO4 respectively. 
ZnCO3, (NH4)2SO4, and Na3PO4 had to be excluded from the formulation in order to 
achieve a zero order kinetics and slow release of drug over an 8 hour period from the 
salted-out PEO combinations. 
 
 
Figure 3.6: Desirability plots depicting the requisite variables for producing a salted-out PEO 
sample with the desired targeted responses. 
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The optimized formulation demonstrated ideal zero-order kinetics of drug release 
over a period of 12 hours (Figure 3.8). The actual release profile of diphenhydramine 
HCl from native PEO in is demonstrated in Figure 3.7. 
 
The salting-out of PEO notably modified the physicochemical and molecular 
structural properties of basic PEO, which demonstrably enhanced the ability of the 
sample to achieve controlled drug release. The synchronized optimization of the 
resilience, fracture force and work performed for the salted-out PEO sample has 
facilitated the achievement of zero-order kinetics. Results have established that 
equal concentrations of Na2CO3 and K2HPO4 are desirable for achieving controlled 
release of drug from the salted-out PEO sample in a zero-order manner. 
Furthermore, Na2CO3 and K2HPO4 has a significant influence on controlling the 
release of drug from the salted-out PEO sample due to strong ionic interactions and 
bond formation between the PEO-chains and the presence of electrolytes ultimately 
leading to zero-order release kinetics.  
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Figure 3.7: Profile of native PEO with Diphenhydramine HCL in PBS (pH 6.8, 37°C). 
 
 
 
Figure 3.8: Profile of Diphenhydramine HCL displaying zero-order release from an optimized 
salted-out PEO-electrolyte sample in PBS (pH 6.8, 37°C). 
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SECTION 4 
CONCLUSIONS AND RECOMMENDATIONS 
 
4.1 Conclusions 
 
This study explored the formulation of PEO-electrolyte combinations which were 
successfully prepared by combining a high molecular weight PEO with different 
statistically planned combinations of electrolytes. The statistical Box-Behnken design 
was employed to derive the 36 experimental formulation combinations of the 
independent formulation variables. The 36 formulations were microscopically 
analyzed and subjected to textural analysis. The salted-out PEO-electrolyte 
combinations were then further selected and analyzed. Assessment of the molecular 
structural transition and thermal compatibility analysis indicated minimal interaction 
between the electrolytes and PEO indicating that the polymer-electrolyte combination 
was stable enough to be employed as a medium for controlled drug release. In vitro 
drug release varied depending on the different electrolytes and their combinations. 
The type of polymer, molecular weight of the polymer, concentration of the polymer, 
different electrolyte combinations and solubility of the drug played a significant role in 
controlling drug release. After optimization of the fracture force, resilience and work 
performed values, results have established that equal concentrations of Na2CO3 and 
K2HPO4 are desirable for achieving controlled release of drug from the salted-out 
PEO combination in a zero-order manner. Furthermore, Na2CO3 and K2HPO4 had a 
significant influence on controlling the release of drug from the salted-out PEO 
combination due to crosslinking between PEO and the electrolytes ultimately leading 
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to zero-order release kinetics. The salting-out of PEO notably modified the 
physicochemical and micromechanical properties of basic PEO, which demonstrably 
enhanced the ability of the sample to achieve controlled drug release. The 
formulation strategy employed in this study where in our sample drug, 
diphenhydramine HCl was combined with a PEO-electrolyte combination has shown 
promising results in regulating drug release. 
 
4.2 Recommendations 
 
Further in depth characterization of the physicochemical and mechanical properties 
e.g., porosity and rheology of the optimized system may be conducted. In-vivo 
studies comparing the release of diphenhydramine HCl from the optimized 
formulation and the currently marketed diphenhydramine HCl formulations may also 
be conducted to determine differences in the bioavailability and the release patterns 
of the drug. The effects of increasing the electrolyte to polymer ratio and decreasing 
the electrolyte to polymer ratio should be investigated to determine the effect on the 
release.  
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